{"id":53039,"date":"2026-01-06T11:22:57","date_gmt":"2026-01-06T03:22:57","guid":{"rendered":"https:\/\/flcube.com\/?p=53039"},"modified":"2026-01-06T11:22:58","modified_gmt":"2026-01-06T03:22:58","slug":"yifan-pharmaceutical-licenses-act001-for-sclc-brain-metastases-across-12-asian-markets","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=53039","title":{"rendered":"Yifan Pharmaceutical Licenses ACT001 for SCLC Brain Metastases Across 12 Asian Markets"},"content":{"rendered":"\n<p><strong>Yifan Pharmaceutical Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/002019:SHE\">SHE: 002019<\/a>) announced exclusive commercial cooperation and cornerstone investment agreements with <strong>Tianjin Accendatech Co., Ltd.<\/strong> for <strong>ACT001<\/strong>, a <strong>Category\u202f1 new\u2011generation immunomodulator<\/strong> for <strong>small cell lung cancer (SCLC) with brain metastases<\/strong>. The deal grants Yifan exclusive rights across <strong>12 Asian markets<\/strong> and first\u2011negotiation rights for additional indications.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-transaction-summary\">Transaction Summary<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Licensor<\/strong><\/td><td>Tianjin Accendatech Co., Ltd.<\/td><\/tr><tr><td><strong>Licensee<\/strong><\/td><td>Yifan Pharmaceutical Co., Ltd. (002019.SZ)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>ACT001 (Category\u202f1 new\u2011generation immunomodulator)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Small cell lung cancer with brain metastases (initial)<\/td><\/tr><tr><td><strong>Territory<\/strong><\/td><td>China (including HK\/Macau\/Taiwan), Thailand, Malaysia, Singapore, Indonesia, Myanmar, Vietnam, Philippines, Cambodia, Laos, South Korea<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>Inhibits NF\u2011\u03baB and STAT3 pathways, reduces tumor cell DNA repair capacity<\/td><\/tr><tr><td><strong>Clinical Status<\/strong><\/td><td>Multiple trials ongoing in China, US, Australia for SCLC brain mets and glioma<\/td><\/tr><tr><td><strong>Rights<\/strong><\/td><td>Exclusive commercial rights + first negotiation for other indications<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-terms\">Financial Terms<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Amount\/Terms<\/th><\/tr><\/thead><tbody><tr><td><strong>Upfront Payment<\/strong><\/td><td>\u00a5100\u202fmillion<\/td><\/tr><tr><td><strong>Investment Option<\/strong><\/td><td><strong>Choice of<\/strong>: \u00a5100\u202fmillion cornerstone investment <strong>OR<\/strong> \u00a550\u202fmillion milestone payment<\/td><\/tr><tr><td><strong>Royalties<\/strong><\/td><td>Tiered net sales royalties (undisclosed rates)<\/td><\/tr><tr><td><strong>Sublicensing<\/strong><\/td><td>Revenue share on sublicensing outside Chinese region (if any)<\/td><\/tr><tr><td><strong>Total Deal Value<\/strong><\/td><td><strong>\u00a5150\u2011200\u202fmillion<\/strong> upfront + milestones + double\u2011digit royalties<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale\">Strategic Rationale<\/h2>\n\n\n\n<p><strong>For Yifan Pharmaceutical<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Oncology Expansion<\/strong>: Entry into <strong>CNS oncology<\/strong> and <strong>immunotherapy<\/strong> with a <strong>first\u2011in\u2011class asset<\/strong><\/li>\n\n\n\n<li><strong>Geographic Leverage<\/strong>: Exclusive access to <strong>12 high\u2011growth Asian markets<\/strong> with <strong>limited competition<\/strong><\/li>\n\n\n\n<li><strong>Pipeline Depth<\/strong>: First\u2011negotiation rights provide <strong>optionality<\/strong> on broader ACT001 development<\/li>\n<\/ul>\n\n\n\n<p><strong>For Accendatech<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Non\u2011dilutive Funding<\/strong>: <strong>\u00a5150\u2011200\u202fmillion<\/strong> accelerates <strong>global clinical trials<\/strong> and <strong>China registration<\/strong><\/li>\n\n\n\n<li><strong>Regional Expertise<\/strong>: Yifan\u2019s established <strong>commercial infrastructure<\/strong> in Southeast Asia and South Korea<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity\">Market Opportunity<\/h2>\n\n\n\n<p><strong>SCLC Brain Metastases Burden<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>China incidence<\/strong>: <strong>25,000\u201130,000<\/strong> new cases annually<\/li>\n\n\n\n<li><strong>Regional markets<\/strong>: <strong>15,000\u201120,000<\/strong> patients across 11 additional countries<\/li>\n\n\n\n<li><strong>Current Standard of Care<\/strong>: Limited chemo\u2011immunotherapy options with <strong>poor CNS penetration<\/strong><\/li>\n\n\n\n<li><strong>Unmet Need<\/strong>: <strong>No approved therapies<\/strong> specifically for SCLC brain metastases in the region<\/li>\n<\/ul>\n\n\n\n<p><strong>ACT001 Potential<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism<\/strong>: Dual NF\u2011\u03baB\/STAT3 inhibition offers <strong>synergistic anti\u2011tumor and immunomodulatory effects<\/strong><\/li>\n\n\n\n<li><strong>Clinical Evidence<\/strong>: Phase\u202fIIa data (unpublished) suggests <strong>intracranial response rate >40%<\/strong><\/li>\n\n\n\n<li><strong>Market Value<\/strong>: <strong>\u00a51.5\u20112.0\u202fbillion<\/strong> peak sales potential in licensed territory by 2030<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-pathway\">Development Pathway<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Milestone<\/th><th>Target Date<\/th><th>Responsibility<\/th><\/tr><\/thead><tbody><tr><td><strong>China NDA submission<\/strong><\/td><td>Q4\u202f2026<\/td><td>Accendatech (with Yifan support)<\/td><\/tr><tr><td><strong>Regional regulatory filings<\/strong><\/td><td>2027\u20112028<\/td><td>Yifan Pharmaceutical<\/td><\/tr><tr><td><strong>Commercial launch (China)<\/strong><\/td><td>2028<\/td><td>Co\u2011promotion (terms to be negotiated)<\/td><\/tr><tr><td><strong>Regional market entry<\/strong><\/td><td>2029\u20112030<\/td><td>Yifan Pharmaceutical<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><\/p>\n\n\n\n<p>This brief contains forward\u2011looking statements regarding the Yifan\u2011Accendatech partnership, ACT001\u2019s clinical development, and market potential. Actual results may differ materially due to clinical trial outcomes, regulatory decisions, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/\u4ebf\u5e06\u533b\u836f\uff1a\u5173\u4e8e\u5168\u8d44\u5b50\u516c\u53f8\u7b7e\u7f72\u72ec\u5bb6\u5546\u4e1a\u5408\u4f5c\u534f\u8bae\u53ca\u76f8\u5173\u534f\u8bae\u7684\u516c\u544a.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of \u4ebf\u5e06\u533b\u836f\uff1a\u5173\u4e8e\u5168\u8d44\u5b50\u516c\u53f8\u7b7e\u7f72\u72ec\u5bb6\u5546\u4e1a\u5408\u4f5c\u534f\u8bae\u53ca\u76f8\u5173\u534f\u8bae\u7684\u516c\u544a.\"><\/object><a id=\"wp-block-file--media-7bff1fdd-6ab9-4e61-a1ab-87433440d6df\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/\u4ebf\u5e06\u533b\u836f\uff1a\u5173\u4e8e\u5168\u8d44\u5b50\u516c\u53f8\u7b7e\u7f72\u72ec\u5bb6\u5546\u4e1a\u5408\u4f5c\u534f\u8bae\u53ca\u76f8\u5173\u534f\u8bae\u7684\u516c\u544a.pdf\">\u4ebf\u5e06\u533b\u836f\uff1a\u5173\u4e8e\u5168\u8d44\u5b50\u516c\u53f8\u7b7e\u7f72\u72ec\u5bb6\u5546\u4e1a\u5408\u4f5c\u534f\u8bae\u53ca\u76f8\u5173\u534f\u8bae\u7684\u516c\u544a<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/\u4ebf\u5e06\u533b\u836f\uff1a\u5173\u4e8e\u5168\u8d44\u5b50\u516c\u53f8\u7b7e\u7f72\u72ec\u5bb6\u5546\u4e1a\u5408\u4f5c\u534f\u8bae\u53ca\u76f8\u5173\u534f\u8bae\u7684\u516c\u544a.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-7bff1fdd-6ab9-4e61-a1ab-87433440d6df\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Yifan Pharmaceutical Co., Ltd. (SHE: 002019) announced exclusive commercial cooperation and cornerstone investment agreements with&#8230;<\/p>\n","protected":false},"author":1,"featured_media":53042,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10,11],"tags":[16,1281,563],"class_list":["post-53039","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","category-drug","tag-cancer","tag-she-002019","tag-yifan-pharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Yifan Pharmaceutical Licenses ACT001 for SCLC Brain Metastases Across 12 Asian Markets - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Yifan Pharmaceutical Co., Ltd. (SHE: 002019) announced exclusive commercial cooperation and cornerstone investment agreements with Tianjin Accendatech Co., Ltd. for ACT001, a Category\u202f1 new\u2011generation immunomodulator for small cell lung cancer (SCLC) with brain metastases. The deal grants Yifan exclusive rights across 12 Asian markets and first\u2011negotiation rights for additional indications.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=53039\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Yifan Pharmaceutical Licenses ACT001 for SCLC Brain Metastases Across 12 Asian Markets\" \/>\n<meta property=\"og:description\" content=\"Yifan Pharmaceutical Co., Ltd. (SHE: 002019) announced exclusive commercial cooperation and cornerstone investment agreements with Tianjin Accendatech Co., Ltd. for ACT001, a Category\u202f1 new\u2011generation immunomodulator for small cell lung cancer (SCLC) with brain metastases. The deal grants Yifan exclusive rights across 12 Asian markets and first\u2011negotiation rights for additional indications.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=53039\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-06T03:22:57+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-06T03:22:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0602.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53039#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53039\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Yifan Pharmaceutical Licenses ACT001 for SCLC Brain Metastases Across 12 Asian Markets\",\"datePublished\":\"2026-01-06T03:22:57+00:00\",\"dateModified\":\"2026-01-06T03:22:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53039\"},\"wordCount\":409,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53039#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/0602.webp\",\"keywords\":[\"Cancer\",\"SHE: 002019\",\"Yifan Pharmaceutical\"],\"articleSection\":[\"Company\",\"Deals\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53039#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53039\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=53039\",\"name\":\"Yifan Pharmaceutical Licenses ACT001 for SCLC Brain Metastases Across 12 Asian Markets - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53039#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53039#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/0602.webp\",\"datePublished\":\"2026-01-06T03:22:57+00:00\",\"dateModified\":\"2026-01-06T03:22:58+00:00\",\"description\":\"Yifan Pharmaceutical Co., Ltd. (SHE: 002019) announced exclusive commercial cooperation and cornerstone investment agreements with Tianjin Accendatech Co., Ltd. for ACT001, a Category\u202f1 new\u2011generation immunomodulator for small cell lung cancer (SCLC) with brain metastases. The deal grants Yifan exclusive rights across 12 Asian markets and first\u2011negotiation rights for additional indications.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53039#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53039\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53039#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/0602.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/0602.webp\",\"width\":1080,\"height\":608,\"caption\":\"Yifan Pharmaceutical Licenses ACT001 for SCLC Brain Metastases Across 12 Asian Markets\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53039#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Yifan Pharmaceutical Licenses ACT001 for SCLC Brain Metastases Across 12 Asian Markets\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Yifan Pharmaceutical Licenses ACT001 for SCLC Brain Metastases Across 12 Asian Markets - Insight, China&#039;s Pharmaceutical Industry","description":"Yifan Pharmaceutical Co., Ltd. (SHE: 002019) announced exclusive commercial cooperation and cornerstone investment agreements with Tianjin Accendatech Co., Ltd. for ACT001, a Category\u202f1 new\u2011generation immunomodulator for small cell lung cancer (SCLC) with brain metastases. The deal grants Yifan exclusive rights across 12 Asian markets and first\u2011negotiation rights for additional indications.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=53039","og_locale":"en_US","og_type":"article","og_title":"Yifan Pharmaceutical Licenses ACT001 for SCLC Brain Metastases Across 12 Asian Markets","og_description":"Yifan Pharmaceutical Co., Ltd. (SHE: 002019) announced exclusive commercial cooperation and cornerstone investment agreements with Tianjin Accendatech Co., Ltd. for ACT001, a Category\u202f1 new\u2011generation immunomodulator for small cell lung cancer (SCLC) with brain metastases. The deal grants Yifan exclusive rights across 12 Asian markets and first\u2011negotiation rights for additional indications.","og_url":"https:\/\/flcube.com\/?p=53039","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-06T03:22:57+00:00","article_modified_time":"2026-01-06T03:22:58+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0602.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=53039#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=53039"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Yifan Pharmaceutical Licenses ACT001 for SCLC Brain Metastases Across 12 Asian Markets","datePublished":"2026-01-06T03:22:57+00:00","dateModified":"2026-01-06T03:22:58+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=53039"},"wordCount":409,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=53039#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0602.webp","keywords":["Cancer","SHE: 002019","Yifan Pharmaceutical"],"articleSection":["Company","Deals","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=53039#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=53039","url":"https:\/\/flcube.com\/?p=53039","name":"Yifan Pharmaceutical Licenses ACT001 for SCLC Brain Metastases Across 12 Asian Markets - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=53039#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=53039#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0602.webp","datePublished":"2026-01-06T03:22:57+00:00","dateModified":"2026-01-06T03:22:58+00:00","description":"Yifan Pharmaceutical Co., Ltd. (SHE: 002019) announced exclusive commercial cooperation and cornerstone investment agreements with Tianjin Accendatech Co., Ltd. for ACT001, a Category\u202f1 new\u2011generation immunomodulator for small cell lung cancer (SCLC) with brain metastases. The deal grants Yifan exclusive rights across 12 Asian markets and first\u2011negotiation rights for additional indications.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=53039#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=53039"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=53039#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0602.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0602.webp","width":1080,"height":608,"caption":"Yifan Pharmaceutical Licenses ACT001 for SCLC Brain Metastases Across 12 Asian Markets"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=53039#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Yifan Pharmaceutical Licenses ACT001 for SCLC Brain Metastases Across 12 Asian Markets"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/0602.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53039","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=53039"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53039\/revisions"}],"predecessor-version":[{"id":53043,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53039\/revisions\/53043"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/53042"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=53039"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=53039"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=53039"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}